| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803043201018 | 304320101 | VAPICAIN INJ.SOL 2MG/ML BTx5 VIALS x 10 ML | 3.17 | 3.33 | 4.59 |
| 05/2018 | 2803043201032 | 304320103 | VAPICAIN INJ.SOL 2MG/ML BTx5 VIALS x 20 ML | 05.07 | 5.32 | 7.34 |
| 05/2018 | 2803043202015 | 304320201 | VAPICAIN INJ.SOL 7,5MG/ML BTx5 VIALS x 10 ML | 5.40 | 5.66 | 7.80 |
| 05/2018 | 2803043202039 | 304320203 | VAPICAIN INJ.SOL 7,5MG/ML BTx5 VIALS x 20 ML | 8.50 | 8.92 | 12.29 |
| 05/2018 | 2803043203012 | 304320301 | VAPICAIN INJ.SOL 10MG/ML BTx5 VIALS x 10 ML | 5.71 | 5.99 | 8.26 |
| 05/2018 | 2803043203036 | 304320303 | VAPICAIN INJ.SOL 10MG/ML BTx5 VIALS x 20 ML | 10.00 | 10.49 | 14.46 |
| 05/2018 | 2803043204019 | 304320401 | VAPICAIN SOL.INF 2MG/ML BTx5 BAGS x 100 ML | 13.01 | 13.65 | 18.82 |
| 05/2018 | 2803043204026 | 304320402 | VAPICAIN SOL.INF 2MG/ML BTx5 BAGS x 200 ML | 23.84 | 25.01 | 34.46 |
Used in obstetric anesthesia and regional anesthesia for surgery.
Local anesthetics such as Ropivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Specifically, they block the sodium-channel and decrease chances of depolarization and consequent action potentials. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.
Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.
Bioavailability is 87%–98% following epidural administration.
Approximately 4.2 hours.
Ropivacaine is extensively metabolized in the liver, predominantly by aromatic hydroxylation mediated by cytochrome P4501A to 3-hydroxy ropivacaine. After a single IV dose approximately 37% of the total dose is excreted in the urine as both free and conjugated 3-hydroxy ropivacaine. In total, 86% of the ropivacaine dose is excreted in the urine after intravenous administration of which only 1% relates to unchanged drug.
* 387 +/- 107 mL/min * unbound plasma clearance=7.2 +/- 1.6 L/min